Can Wegovy Cause Cancer? What the Clinical Evidence Actually Shows

Step 1: understand what the thyroid warning on the Wegovy label actually means

When people ask whether Wegovy can cause cancer, the question is usually prompted by something they read in the patient information leaflet. The leaflet lists a warning about thyroid C-cell tumours, and that warning is real — but the context matters.

The signal originated in animal studies. When semaglutide was tested in rodents at doses and over durations that far exceed typical human exposure, C-cell tumours of the thyroid were observed. Regulatory agencies including the MHRA required this to be reflected in the product information as a precaution. What the data do not show is that this effect has been reproduced in humans. The large clinical trials that supported Wegovy's licence (involving thousands of participants over 68 weeks) did not find an elevated rate of thyroid cancer. The NHS medicines page for semaglutide notes this distinction.

Because the human relevance of the rodent finding is uncertain, Wegovy remains contraindicated for people with a personal or family history of medullary thyroid carcinoma (MTC), or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). These contraindications exist precisely because, in the absence of definitive human data, regulators apply the precautionary exclusions where a biological plausibility exists. If either of those conditions applies to you, a prescriber will identify this during your clinical assessment, and our dedicated page on Wegovy and cancer explains in more detail how these exclusions are applied in practice.

Step 2: look at what the broader human evidence does (and does not) show

A question our prescribers hear most weeks is whether the research on semaglutide and cancer risk points in one direction or two. The honest answer is that it points in several directions at once, and that is exactly what early evidence looks like.

The STEP 1 trial, published in the New England Journal of Medicine, was powered to detect weight-loss outcomes, not cancer incidence, so it was not designed to answer this question definitively. Separately, some observational studies and data analyses have suggested that semaglutide users may have a lower incidence of certain obesity-related cancers compared with matched populations. Obesity itself is a recognised risk factor for more than a dozen cancer types, so a medicine that produces substantial, sustained weight reduction might plausibly reduce that background risk over time. These are hypothesis-generating findings, not conclusions, and no UK regulator has endorsed a cancer-protective claim for Wegovy.

You can read more about the broader evidence landscape on our page covering semaglutide and cancer risk, which draws together both the thyroid signal and the emerging observational data in one place. For a general overview of Wegovy's profile, the Wegovy treatment page covers eligibility, how the medicine works, and what clinical trials reported for weight outcomes.

Step 3: know what current UK regulatory oversight looks like

Wegovy carries a Black Triangle (▼) designation in the UK. This does not mean the medicine is considered especially dangerous; it means the MHRA requires enhanced post-market surveillance because the medicine is relatively new to widespread use. Every healthcare professional and patient is encouraged to report suspected side effects (including any new diagnoses) through the Yellow Card scheme.

This ongoing monitoring is how regulators detect signals that may not have been visible in controlled trials. If a meaningful cancer signal emerged in real-world use, the MHRA would publish a Drug Safety Update and, where warranted, update the product's prescribing information. No such update on cancer has been issued to date.

Anyone considering weight-management treatment who has existing cancer concerns, a relevant family history, or has previously been treated for any cancer should discuss this with a prescriber before starting. The clinical assessment process at a regulated pharmacy is precisely where those conversations happen, and if you are exploring roles within that process, our page listing Wegovy-related jobs sets out the positions currently available. If you are thinking about the practicalities of treatment, our page on Wegovy costs in the UK covers what a private prescription typically involves.

Step 4: situate this in the wider picture of Wegovy's known side-effect profile

Most of Wegovy's well-characterised side effects are gastrointestinal: nausea, constipation, loose stools, reflux and stomach discomfort are the most commonly reported, particularly in the early weeks of treatment or after a dose increase. These are covered in detail on the Wegovy side effects overview. Cancer does not appear on the list of recognised, established adverse effects from human data.

That framing matters. There is a difference between a theoretical caution noted in animal data (the thyroid C-cell signal), an area of active scientific interest (whether weight loss via GLP-1 medicines might lower obesity-related cancer risk), and a confirmed harm established in humans, and Wegovy and cancer currently sits in neither of the last two categories as a confirmed harm.

If a symptom concerns you during treatment (thyroid-related or otherwise) speak to a clinician promptly rather than stopping the medicine unilaterally. And if you have questions about whether Wegovy is appropriate given your own health history, speaking to our prescribers through a free consultation is the right starting point.